Early Prediction of Bronchopulmonary Dysplasia in Preterm Infants Using Clinical Data

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age0-28
SponsorKonya City Hospital

About this trial

Early Prediction of Bronchopulmonary Dysplasia in Preterm Infants Using Clinical Data from the First Three Postnatal Weeks with Large Language Models: A Retrospective Study This retrospective, observational study aims to evaluate the early prediction of bronchopulmonary dysplasia (BPD) in preterm infants using clinical data from the first, second, and third postnatal weeks. The study includes infants born before 32 weeks of gestation or weighing less than 1,500 grams, followed at the Neonatal Intensive Care Unit of Konya City Hospital.

The study will compare the performance of different large language models (LLMs), including ChatGPT, Gemini, and Claude, in predicting BPD development. Clinical variables such as gestational age, birth weight, respiratory support, oxygen requirement, mechanical ventilation duration, and infection status will be used.

Primary outcome: Accuracy of BPD risk prediction by each AI model compared to actual clinical outcomes. Secondary outcomes: Sensitivity and specificity of predictions, weekly prediction performance, and comparative performance among AI models.

The results will provide insight into the potential clinical utility of AI-based approaches for early BPD risk assessment in preterm infants.

Eligibility criteria

Qualifiers

Preterm infants born before 32 weeks of gestation or with birth weight <1,500 grams

Admitted and followed in the Neonatal Intensive Care Unit (NICU) of Konya City Hospital

Availability of complete clinical data in hospital records

Documented bronchopulmonary dysplasia (BPD) outcome status

Disqualifiers

Presence of major congenital anomalies

Incomplete or missing clinical data

Death shortly after birth with insufficient follow-up data to determine BPD status

Trial design

Treatments tested in this trial

  • Artificial Intelligence-Based Risk Prediction

Treatment groups

108 Participants
are divided into 1 treatment group

Sponsors and collaborators